Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy

Saved in:
Bibliographic Details
Main Authors: Jesse Haramati, Fabiola Solorzano-Ibarra, Dallas B. Flies
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1563383/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823859177064235008
author Jesse Haramati
Fabiola Solorzano-Ibarra
Fabiola Solorzano-Ibarra
Dallas B. Flies
author_facet Jesse Haramati
Fabiola Solorzano-Ibarra
Fabiola Solorzano-Ibarra
Dallas B. Flies
author_sort Jesse Haramati
collection DOAJ
format Article
id doaj-art-650ef046679c47a1bd0fb63101fcb57f
institution Kabale University
issn 1664-3224
language English
publishDate 2025-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-650ef046679c47a1bd0fb63101fcb57f2025-02-11T07:00:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15633831563383Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapyJesse Haramati0Fabiola Solorzano-Ibarra1Fabiola Solorzano-Ibarra2Dallas B. Flies3Laboratorio de Inmunología Traslacional, Departamento de Biología Celular y Molecular, Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Zapopan, Jalisco, MexicoEstancias Posdoctorales por México, Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONACHYT), México City, MexicoInstituto en Investigación en Enfermedades Crónico Degenerativas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, MexicoNextCure, Inc., Beltsville, MD, United Stateshttps://www.frontiersin.org/articles/10.3389/fimmu.2025.1563383/fullICI Immunotherapycancertumorpersonalized & precision medicinecheckpoint blockade (ICB) therapy
spellingShingle Jesse Haramati
Fabiola Solorzano-Ibarra
Fabiola Solorzano-Ibarra
Dallas B. Flies
Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
Frontiers in Immunology
ICI Immunotherapy
cancer
tumor
personalized & precision medicine
checkpoint blockade (ICB) therapy
title Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
title_full Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
title_fullStr Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
title_full_unstemmed Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
title_short Editorial: Beyond PD-1: novel checkpoint receptors and ligands as targets for immunotherapy
title_sort editorial beyond pd 1 novel checkpoint receptors and ligands as targets for immunotherapy
topic ICI Immunotherapy
cancer
tumor
personalized & precision medicine
checkpoint blockade (ICB) therapy
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1563383/full
work_keys_str_mv AT jesseharamati editorialbeyondpd1novelcheckpointreceptorsandligandsastargetsforimmunotherapy
AT fabiolasolorzanoibarra editorialbeyondpd1novelcheckpointreceptorsandligandsastargetsforimmunotherapy
AT fabiolasolorzanoibarra editorialbeyondpd1novelcheckpointreceptorsandligandsastargetsforimmunotherapy
AT dallasbflies editorialbeyondpd1novelcheckpointreceptorsandligandsastargetsforimmunotherapy